查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1827807

2025年全球藥物-器械組合市場報告

Drug Device Combination Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

近年來，藥械組合市場快速擴張，規模從2024年的1,310.1億美元成長至2025年的1,442.2億美元，複合年成長率為10.1%。預測期內的成長可歸因於醫療創新的不斷增加、慢性病的增加、以患者為中心的診療方法、生技藥品的進步、單一療法的挑戰以及臨床需求。

預計未來幾年，藥械組合市場規模將快速成長，到2029年將達到2,246.8億美元，複合年成長率為11.7%。預測期內的成長可歸因於患者賦權和參與、醫療保健數位化、全球市場不斷擴張、新型治療方法的湧現以及基於價值的醫療保健。預測期內的主要趨勢包括治療進展、複雜疾病管理、以患者為中心的護理、技術創新以及監管支持。

藥物-醫療設備組合是指將醫療設備與藥物結合的治療或診斷產品，旨在實現局部給藥、精準標靶給藥和個人化治療。這些組合構成一個物理和化學上統一的實體，並被包裝在一起。藥物-器械組合在臨床開發中發揮重要作用，能夠將藥物輸送到體內的特定部位。

主要的藥械組合產品類型包括自動注射器、微針貼片、數位藥丸、智慧吸入器、藥物輸送水凝膠和藥物釋放型鏡片。這些產品應用於整形外科、呼吸系統疾病、糖尿病、腫瘤科和心血管疾病等多個醫療領域。藥械組合產品的最終用戶包括診所、醫院、居家照護機構和門診護理中心。這些產品透過直接競標、零售和其他分銷管道分銷。

2025年春季，美國關稅突然上調及其引發的貿易摩擦對醫療設備產業產生了重大影響，尤其對用於診斷影像設備的進口零件、手術用不銹鋼和一次性塑膠製品產生了重大影響。由於醫院和診所抵制漲價，製造商面臨利潤壓力。監管挑戰使情況更加複雜，因為由於關稅而更換供應商通常需要重新認證醫療設備，導致市場進入延遲。為此，企業正在透過雙重採購關鍵零件、增加標準產品的國內生產以及加快研發更具成本效益的材料來降低風險。

本研究報告是商業研究公司（The Business Research Company）新報告系列的一部分，該系列提供藥械組合市場統計數據，例如全球市場規模、區域佔有率、藥械組合市場佔有率的競爭對手、詳細的藥械組合市場細分、市場趨勢和商業機會，以及在藥械組合行業取得成功所需的數據。本研究報告對產業現狀和未來趨勢進行了詳細分析，提供您所需的所有資訊。

我們預測未來五年該市場將成長11.7%，較先前預測略有下降0.2%。這一下降主要源自於美國與其他國家之間關稅的影響。美國可能會直接感受到這種影響，因為來自荷蘭和瑞典等主要地區的藥物塗層聚合物基質和組合藥物包裝的供應鏈將中斷，從而導致美國食品藥物管理局(FDA)核准延遲，並增加整合療法的開發成本。由於互惠關稅以及不斷升級的貿易摩擦和限制對全球經濟和貿易的負面影響，這種影響也將更加廣泛。

由於慢性病的盛行率不斷上升，藥物-醫療設備組合市場正在經歷顯著成長。慢性病是指持續一年以上且需要持續醫療照護的疾病，包括心臟病和糖尿病等。治療和診斷組合在有效治療慢性病患者方面發揮著至關重要的作用。根據世界衛生組織 (WHO) 的報告，預計到 2022 年，全球糖尿病患者人數將超過 4.2 億，到 2030 年將增至 5.78 億，到 2045 年將達到 7 億。盛行率的上升凸顯了藥物-器械組合在慢性病管理中的關鍵作用，從而推動了市場的成長。

預計未來事故死亡和受傷人數的增加將推動藥械聯合治療市場的成長。事故是指意外或非計劃發生的事件，會導致非故意的傷害、損壞、損傷或損失，通常是由人為錯誤、疏忽、環境條件和機械故障等多種因素造成的。藥物醫療設備組合對於管理和預防事故至關重要，因為它可以提供有針對性的醫療干預措施並提高病人安全性。例如，2024 年 5 月，加拿大政府機構加拿大運輸部報告稱，2022 年機動車事故死亡人數將達到 1,931 人，比總合一年的 1,821 人增加 6.0%，是過去十年中的第二高。因此，事故死亡和受傷人數的增加正在推動藥械聯合治療市場的發展。

藥械組合市場涵蓋導管和高級創傷護理產品的銷售。該市場的價值為“出廠價”，即產品製造商或生產商向其他營業單位（包括下游製造商、批發商、經銷商和零售商）或直接向最終客戶銷售的產品價值。該市場的產品價值還包括產品製造商提供的任何相關服務。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球製藥設備市場：PESTEL 分析（政治、社會、技術、環境、法律因素、促進因素和限制因素）
  • 最終用途產業分析
  • 全球藥械組合市場：成長率分析
  • 全球藥物-器械組合市場表現：規模與成長，2019-2024
  • 全球藥械組合市場預測：2024-2029年及2034年規模與成長
  • 全球藥物-器械組合：總目標市場（TAM）

第6章 市場細分

  • 全球藥物-器材組合市場：依產品、實際狀況及預測，2019-2024 年、2024-2029 年、2034 年
  • 自動注射器
  • 微針貼片
  • 數字藥丸
  • 智慧吸入器
  • 藥物輸送水凝膠
  • 藥物釋放型鏡片
  • 其他產品
  • 全球藥物-器材組合市場：按分銷管道、實際和預測，2019-2024 年、2024-2029 年、2034 年
  • 直接競標
  • 零售額
  • 其他分銷管道
  • 全球藥械組合市場：依應用、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 整形外科疾病
  • 呼吸系統疾病
  • 糖尿病
  • 腫瘤學
  • 心血管疾病
  • 其他用途
  • 全球藥物-器械組合市場：按最終用戶、實際和預測，2019-2024 年、2024-2029 年、2034 年
  • 診所
  • 醫院
  • 居家照護環境
  • 門診治療中心
  • 其他最終用戶
  • 全球藥物-設備組合市場：依自動注射器類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 預填充自動注射器
  • 可重複使用的自動注射器
  • 全球藥物-設備組合市場：按微針貼片類型、性能和預測細分，2019-2024 年、2024-2029 年、2034 年
  • 可溶性微針貼片
  • 塗層微針貼片
  • 全球藥械組合市場：按數字藥丸細分，類型，實際和預測，2019-2024 年，2024-2029 年，2034 年
  • 可攝入感測器
  • 智慧膠囊
  • 全球藥物-設備組合市場：智慧吸入器的細分（按類型）、實際和預測，2019-2024 年、2024-2029 年、2034 年
  • 定量噴霧吸入器（MDI）
  • 乾粉吸入器（DPI）
  • 全球藥物-器械組合市場：按藥物輸送水凝膠（按類型）細分、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 可注射水凝膠
  • 外用水凝膠
  • 全球藥物-器械組合市場：藥物釋放型鏡片細分（按類型）、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 隱形眼鏡
  • 人工水晶體
  • 全球藥物-器材組合市場：依產品類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 經皮吸收貼片
  • 植入式藥物傳輸系統

第7章 區域和國家分析

  • 全球藥物-器材組合市場：依地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球藥物-器械組合市場：按國家、實際結果和預測，2019-2024 年、2024-2029 年、2034 年

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 藥物-器材組合市場：競爭格局
  • 藥物-器械組合市場：公司簡介
    • The 3M Company Overview, Products and Services, Strategy and Financial Analysis
    • Abbott India Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • Biotronik SE & Co. KG Overview, Products and Services, Strategy and Financial Analysis
    • Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • Medtronic PLC Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Ypsomed Holding AG
  • Micron Biomedical Inc.
  • MetP Pharma AG
  • Sonceboz SA
  • Lepu Medical Technology（Beijing）Co. Ltd.
  • Eitan Medical Ltd.
  • Vaxess Technologies Inc.
  • Subcuject Aps
  • Allergan PLC
  • Terumo Corporation
  • Stryker Corporation
  • Becton Dickinson and Company
  • Zimmer Biomet Holdings Inc.
  • MediPrint Ophthalmics
  • Arrow International Inc.

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029年藥械組合市場：提供新機會的國家
  • 2029年藥械組合市場：細分領域帶來新機會
  • 2029年藥械組合市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r22555u

Drug-device combinations refer to therapeutic and diagnostic products that combine a medical device with a drug, facilitating localized drug administration, precise drug targeting, and personalized therapy. These combinations create a unified entity, physically and chemically, packaged together in a single package. Drug-device combinations play a crucial role in clinical development, enabling the delivery of drugs to specific locations in the body.

The primary types of drug-device combination products include auto-injectors, microneedle patches, digital pills, smart inhalers, drug delivery hydrogels, drug-eluting lenses, and other products. These products find applications in various medical fields such as orthopedic diseases, respiratory diseases, diabetes, oncology, cardiovascular diseases, among others. The end users of drug-device combination products include clinics, hospitals, home care settings, ambulatory care centers, and others. These products are distributed through direct tenders, retail sales, and other distribution channels.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp increase in U.S. tariffs and resulting trade tensions in spring 2025 are significantly impacting the medical equipment sector, especially for imported components used in imaging machines, surgical-grade stainless steel, and disposable plastics. With hospitals and clinics pushing back against price increases, manufacturers are facing margin pressure. The situation is further complicated by regulatory challenges, as switching suppliers due to tariffs often necessitates re-certification of medical devices, leading to delays in market entry. In response, companies are mitigating risks by dual-sourcing key components, ramping up domestic production of standardized items, and accelerating research into more cost-effective materials.

The drug-device combination market research report is one of a series of new reports from The Business Research Company that provides drug-device combination market statistics, including drug-device combination industry global market size, regional shares, competitors with an drug-device combination market share, detailed drug-device combination market segments, market trends and opportunities, and any further data you may need to thrive in the drug-device combination industry. This drug-device combination market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The drug device combination market size has grown rapidly in recent years. It will grow from $131.01 billion in 2024 to $144.22 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to increasing medical innovation, rise in chronic diseases, patient-centric approaches, advances in biologics, challenges of monotherapy, clinical needs.

The drug device combination market size is expected to see rapid growth in the next few years. It will grow to $224.68 billion in 2029 at a compound annual growth rate (CAGR) of 11.7%. The growth in the forecast period can be attributed to patient empowerment and engagement, healthcare digitalization, global market expansion, emergence of novel therapies, value-based healthcare. Major trends in the forecast period include therapeutic advancements, complex disease management, patient-centric care, technological innovations, and regulatory support.

The forecast of 11.7% growth over the next five years indicates a slight reduction of 0.2% from the previous estimate for this market.This reduction is primarily due to the impact of tariffs between the US and other countries. This is likely to directly affect the US through supply chain disruptions for drug-coated polymer matrices and combination product packaging, sourced from key regions such as the Netherlands and Sweden, which could lead to delayed Food and Drug Administration (FDA) approvals and increased development costs for integrated therapies.The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The drug-device combination market is witnessing substantial growth driven by the increasing prevalence of chronic diseases. Chronic diseases, persisting for a year or longer and requiring ongoing medical care, include conditions like heart disease and diabetes. Drug-device combinations, encompassing therapeutic and diagnostic products, play a pivotal role in effectively treating individuals with chronic diseases. As per the World Health Organization's report, the global incidence of diabetes surpassed 420 million in 2022, with projections indicating a rise to 578 million by 2030 and 700 million by 2045. This escalating prevalence underscores the critical role of drug-device combinations in managing chronic diseases, thereby propelling the growth of the market.

An increase in casualties due to accidents is anticipated to drive the growth of the drug-device combination market in the future. Accidents refer to unexpected events or unplanned incidents that result in unintended harm, damage, injury, or loss, often arising from a mix of factors such as human error, negligence, environmental conditions, or mechanical failure. Drug-device combinations are essential in managing and preventing accidents by providing targeted medical interventions and improving patient safety. For example, in May 2024, Transport Canada, a government agency in Canada, reported that motor vehicle fatalities reached 1,931 in 2022, representing a 6.0% increase from the previous year's total of 1,821, and marking the second highest figure recorded in the past decade. Consequently, the rise in casualties resulting from accidents is fueling the drug-device combination market.

Major companies in the drug combination device market are developing innovative products like Trelegy Ellipta to maintain their market position. Trelegy Ellipta is an inhaler designed to deliver a specific dosage of medication directly to the lungs and is recognized as the first single-inhaler triple therapy. For example, in April 2022, GSK, a UK-based pharmaceutical and biotechnology company, introduced Trelegy Ellipta. This inhaler is a compact and portable device used to treat chronic obstructive pulmonary disease (COPD) and asthma. Ellipta inhalers can accommodate up to three different types of drugs in foil packaging for combination therapy. Trelegy Ellipta is a drug combination device that features three active ingredients: fluticasone furoate, umeclidinium, and vilanterol. It enhances patient management of respiratory conditions through its integrated delivery system.

Major companies in the drug-device combination market are introducing innovative products such as the G-Lasta Subcutaneous Injection 3.6 mg BodyPod to simplify the administration process. The G-Lasta Subcutaneous Injection 3.6 mg BodyPod is a drug-device combination that includes an automated injection device and G-Lasta (pegfilgrastim), a medication given to patients undergoing chemotherapy to reduce the occurrence of febrile neutropenia. For instance, in December 2022, Terumo Corporation, a Japan-based medical device company, collaborated with Kyowa Kirin, a Japan-based pharmaceutical company, to launch the G-Lasta Subcutaneous Injection 3.6 mg BodyPod. G-Lasta is utilized during chemotherapy to decrease the incidence of febrile neutropenia. The automated injection device is connected at the hospital on the day of chemotherapy and automatically administers the drug approximately 27 hours later. This feature eliminates the need for an extra outpatient visit, thereby easing the burden on patients.

In May 2023, Closed Loop Medicine Ltd, a UK-based TechBio company focused on developing combination prescription drug and software therapy products, formed a partnership with Pharmanovia. Through this collaboration, Closed Loop Medicine Ltd. aims to advance precision medicine strategies that utilize genetic and molecular profiling to determine the most effective drug combinations for individual patients. Pharmanovia is a pharmaceutical company based in the UK.

Major companies operating in the drug device combination market are The 3M Company, Abbott India Ltd., Biotronik SE & Co. KG, Boston Scientific Corporation, Medtronic PLC, Ypsomed Holding AG, Micron Biomedical Inc., MetP Pharma AG, Sonceboz SA, Lepu Medical Technology (Beijing) Co. Ltd., Eitan Medical Ltd., Vaxess Technologies Inc., Subcuject Aps, Allergan PLC, Terumo Corporation, Stryker Corporation, Becton Dickinson and Company, Zimmer Biomet Holdings Inc., MediPrint Ophthalmics, Arrow International Inc., Alcon Inc., W. L. Gore & Associates Inc., Cook Medical LLC, Pinnacle Biologics Inc.

North America was the largest region in the drug-device combination market share in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the drug device combination market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the drug device combination market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The drug-device combination market consists of sales of catheter and advanced wound care products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Drug Device Combination Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on drug device combination market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for drug device combination ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The drug device combination market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Auto-Injector; Microneedle Patch; Digital Pill; Smart Inhaler; Drug Delivery Hydrogels; Drug-Eluting Lens; Other Products
  • 2) By Distribution Channel: Direct Tender; Retails Sales; Other Distribution Channels
  • 3) By Application: Orthopedic Diseases; Respiratory Diseases; Diabetes; Oncology; Cardiovascular Diseases; Other Applications
  • 4) By End User: Clinics; Hospitals; Home Care Settings; Ambulatory Care Centers; Other End Users
  • Subsegments:
  • 1) By Auto-Injector: Pre-Filled Auto-Injectors; Reusable Auto-Injectors
  • 2) By Microneedle Patch: Dissolving Microneedle Patches; Coated Microneedle Patches
  • 3) By Digital Pill: Ingestible Sensors; Smart Capsules
  • 4) By Smart Inhaler: Metered-Dose Inhalers (MDIs); Dry Powder Inhalers (DPIs)
  • 5) By Drug Delivery Hydrogels: Injectable Hydrogels; Topical Hydrogels
  • 6) By Drug-Eluting Lens: Contact Lenses; Intraocular Lenses
  • 7) By Other Products: Transdermal Patches; Implantable Drug Delivery Systems
  • Companies Mentioned: The 3M Company; Abbott India Ltd.; Biotronik SE & Co. KG; Boston Scientific Corporation; Medtronic PLC; Ypsomed Holding AG; Micron Biomedical Inc.; MetP Pharma AG; Sonceboz SA; Lepu Medical Technology (Beijing) Co. Ltd.; Eitan Medical Ltd.; Vaxess Technologies Inc.; Subcuject Aps; Allergan PLC; Terumo Corporation; Stryker Corporation; Becton Dickinson and Company; Zimmer Biomet Holdings Inc.; MediPrint Ophthalmics; Arrow International Inc.; Alcon Inc.; W. L. Gore & Associates Inc.; Cook Medical LLC; Pinnacle Biologics Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Drug Device Combination Market Characteristics

3. Drug Device Combination Market Trends And Strategies

4. Drug Device Combination Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Drug Device Combination Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Drug Device Combination PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Drug Device Combination Market Growth Rate Analysis
  • 5.4. Global Drug Device Combination Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Drug Device Combination Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Drug Device Combination Total Addressable Market (TAM)

6. Drug Device Combination Market Segmentation

  • 6.1. Global Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Auto-Injector
  • Microneedle Patch
  • Digital Pill
  • Smart Inhaler
  • Drug Delivery Hydrogels
  • Drug-Eluting Lens
  • Other Products
  • 6.2. Global Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Direct Tender
  • Retails Sales
  • Other Distribution Channels
  • 6.3. Global Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Orthopedic Diseases
  • Respiratory Diseases
  • Diabetes
  • Oncology
  • Cardiovascular Diseases
  • Other Applications
  • 6.4. Global Drug Device Combination Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Clinics
  • Hospitals
  • Home Care Settings
  • Ambulatory Care Centers
  • Other End Users
  • 6.5. Global Drug Device Combination Market, Sub-Segmentation Of Auto-Injector, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pre-Filled Auto-Injectors
  • Reusable Auto-Injectors
  • 6.6. Global Drug Device Combination Market, Sub-Segmentation Of Microneedle Patch, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Dissolving Microneedle Patches
  • Coated Microneedle Patches
  • 6.7. Global Drug Device Combination Market, Sub-Segmentation Of Digital Pill, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Ingestible Sensors
  • Smart Capsules
  • 6.8. Global Drug Device Combination Market, Sub-Segmentation Of Smart Inhaler, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Metered-Dose Inhalers (MDIs)
  • Dry Powder Inhalers (DPIs)
  • 6.9. Global Drug Device Combination Market, Sub-Segmentation Of Drug Delivery Hydrogels, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Injectable Hydrogels
  • Topical Hydrogels
  • 6.10. Global Drug Device Combination Market, Sub-Segmentation Of Drug-Eluting Lens, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Contact Lenses
  • Intraocular Lenses
  • 6.11. Global Drug Device Combination Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Transdermal Patches
  • Implantable Drug Delivery Systems

7. Drug Device Combination Market Regional And Country Analysis

  • 7.1. Global Drug Device Combination Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Drug Device Combination Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Drug Device Combination Market

  • 8.1. Asia-Pacific Drug Device Combination Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Drug Device Combination Market

  • 9.1. China Drug Device Combination Market Overview
  • 9.2. China Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Drug Device Combination Market

  • 10.1. India Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Drug Device Combination Market

  • 11.1. Japan Drug Device Combination Market Overview
  • 11.2. Japan Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Drug Device Combination Market

  • 12.1. Australia Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Drug Device Combination Market

  • 13.1. Indonesia Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Drug Device Combination Market

  • 14.1. South Korea Drug Device Combination Market Overview
  • 14.2. South Korea Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Drug Device Combination Market

  • 15.1. Western Europe Drug Device Combination Market Overview
  • 15.2. Western Europe Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Drug Device Combination Market

  • 16.1. UK Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Drug Device Combination Market

  • 17.1. Germany Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Drug Device Combination Market

  • 18.1. France Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Drug Device Combination Market

  • 19.1. Italy Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Drug Device Combination Market

  • 20.1. Spain Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Drug Device Combination Market

  • 21.1. Eastern Europe Drug Device Combination Market Overview
  • 21.2. Eastern Europe Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Drug Device Combination Market

  • 22.1. Russia Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Drug Device Combination Market

  • 23.1. North America Drug Device Combination Market Overview
  • 23.2. North America Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Drug Device Combination Market

  • 24.1. USA Drug Device Combination Market Overview
  • 24.2. USA Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Drug Device Combination Market

  • 25.1. Canada Drug Device Combination Market Overview
  • 25.2. Canada Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Drug Device Combination Market

  • 26.1. South America Drug Device Combination Market Overview
  • 26.2. South America Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Drug Device Combination Market

  • 27.1. Brazil Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Drug Device Combination Market

  • 28.1. Middle East Drug Device Combination Market Overview
  • 28.2. Middle East Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Drug Device Combination Market

  • 29.1. Africa Drug Device Combination Market Overview
  • 29.2. Africa Drug Device Combination Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Drug Device Combination Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Drug Device Combination Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Drug Device Combination Market Competitive Landscape And Company Profiles

  • 30.1. Drug Device Combination Market Competitive Landscape
  • 30.2. Drug Device Combination Market Company Profiles
    • 30.2.1. The 3M Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Abbott India Ltd. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Biotronik SE & Co. KG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Boston Scientific Corporation Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Medtronic PLC Overview, Products and Services, Strategy and Financial Analysis

31. Drug Device Combination Market Other Major And Innovative Companies

  • 31.1. Ypsomed Holding AG
  • 31.2. Micron Biomedical Inc.
  • 31.3. MetP Pharma AG
  • 31.4. Sonceboz SA
  • 31.5. Lepu Medical Technology (Beijing) Co. Ltd.
  • 31.6. Eitan Medical Ltd.
  • 31.7. Vaxess Technologies Inc.
  • 31.8. Subcuject Aps
  • 31.9. Allergan PLC
  • 31.10. Terumo Corporation
  • 31.11. Stryker Corporation
  • 31.12. Becton Dickinson and Company
  • 31.13. Zimmer Biomet Holdings Inc.
  • 31.14. MediPrint Ophthalmics
  • 31.15. Arrow International Inc.

32. Global Drug Device Combination Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Drug Device Combination Market

34. Recent Developments In The Drug Device Combination Market

35. Drug Device Combination Market High Potential Countries, Segments and Strategies

  • 35.1 Drug Device Combination Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Drug Device Combination Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Drug Device Combination Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer